Peptide · Fact sheet
Thymosin beta-4
Also known as Tβ4 · TB4 · full-length thymosin beta-4 · TB-500 (fragment marketed online)
Thymosin beta-4 is a naturally occurring peptide involved in cell movement and tissue processes. Experimental full-length products and the TB-500 fragment marketed online should not be treated as proven or interchangeable therapies.
What is Thymosin beta-4?
Thymosin beta-4 is present in many tissues and has roles involving actin, cell movement, inflammation, and repair signaling.
TB-500 commonly refers to a shorter fragment marketed online. Evidence about full-length thymosin beta-4 cannot automatically be applied to that fragment or to an unverified product.
Benefits & claims
It is discussed for injury recovery, wound healing, heart repair, eye conditions, and athletic performance.
Much of the enthusiasm comes from mechanistic or preclinical research rather than proven clinical outcomes.
What the evidence supports
- Preclinical research suggests roles in cell migration, blood-vessel formation, and tissue repair.
- Early studies do not establish a general injury-recovery or athletic-performance treatment.
Research areas
- Tissue and wound repair
- Corneal healing
- Cardiac repair
- Inflammation
- Cell migration
- Topical and systemic tissue-repair applications in research settings
Dosage & frequency
No established human regimenThymosin beta-4 eye-drop trials do not establish an injectable TB-500 regimen for injury recovery.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
Formulation differences
- Full-length thymosin beta-4, TB-500 fragments, and RGN-259 eye drops are different products and evidence.
Interactions & precautions
- Ophthalmic trial evidence does not establish drug interactions for systemic thymosin beta-4 or TB-500 fragments.
What is still unresolved
- An effective systemic repair dose, frequency, and long-term safety profile remain unestablished.
Side effects & risks
- FDA notes potential immune reactions, aggregation, peptide impurities, and a lack of identified human exposure data for the TB-500 fragment in drug products.
- Systemic effects and long-term consequences are insufficiently understood.
- Online products add identity, purity, sterility, and labeling uncertainty.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Mostly animal or lab researchThere are early human studies in selected areas, but the broad recovery claims seen online are supported mainly by preclinical evidence.
Studies
Registry record for an ophthalmic thymosin beta-4-related study.
Registry record for an additional ophthalmic thymosin beta-4-related study.
Peer-reviewed review discussing thymosin beta-4 in corneal wound healing and inflammation.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
Explore 3 sourced accounts by reported effect.
Sleep: reported experiences
Severe anxiety, sleeplessness and chest tightness
A different person reported these symptoms after exposure to products labeled BPC-157 and TB-500, including seeking hospital assessment.
Reported use in this account
- Product
- Products labeled BPC-157 and TB-500; full-length thymosin beta-4 identity not established
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Subcutaneous injection
- Duration
- Three days before the reported severe reaction
Other exposures described: BPC-157; Propranolol given after symptoms
Combined exposure and unverified product identity prevent attribution to either substance. This is a personal report, not a confirmed drug reaction or an estimate of risk.
Read the adverse-experience reportMood: reported experiences
Severe anxiety, sleeplessness and chest tightness
A different person reported these symptoms after exposure to products labeled BPC-157 and TB-500, including seeking hospital assessment.
Reported use in this account
- Product
- Products labeled BPC-157 and TB-500; full-length thymosin beta-4 identity not established
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Subcutaneous injection
- Duration
- Three days before the reported severe reaction
Other exposures described: BPC-157; Propranolol given after symptoms
Combined exposure and unverified product identity prevent attribution to either substance. This is a personal report, not a confirmed drug reaction or an estimate of risk.
Read the adverse-experience reportPain: reported experiences
No elbow improvement during combined exposure
An author described no improvement in longstanding elbow symptoms after 14 weeks using a product labeled BPC-157/TB-500 alongside rehabilitation exercises.
Reported use in this account
- Product
- Pen labeled BPC-157/TB-500; full-length thymosin beta-4 identity not established
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Fourteen weeks
Other exposures described: BPC-157; Rehabilitation exercises
The exposure units are inconsistent and the product’s contents were not verified. This combined, fragment-labeled product cannot establish the effects of full-length thymosin beta-4.
Read the original accountLess knee pain during combined exposure
One person attributed a gradual reduction in longstanding knee pain to products labeled BPC-157 and TB-500 used together.
Reported use in this account
- Product
- Product labeled TB-500; full-length thymosin beta-4 identity not established
- Amount
- 500 mcg of TB-500 per use day, as reported
- Frequency
- Five days per week
- Route
- Subcutaneous injection
- Duration
- Five weeks at the time of the post
Other exposures described: BPC-157
Two products were used, with no control group or independent assessment of healing. The account cannot separate their effects. TB-500 product labeling does not verify equivalence to full-length thymosin beta-4.
Read the knee-pain reportHeart symptoms: reported experiences
Severe anxiety, sleeplessness and chest tightness
A different person reported these symptoms after exposure to products labeled BPC-157 and TB-500, including seeking hospital assessment.
Reported use in this account
- Product
- Products labeled BPC-157 and TB-500; full-length thymosin beta-4 identity not established
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Subcutaneous injection
- Duration
- Three days before the reported severe reaction
Other exposures described: BPC-157; Propranolol given after symptoms
Combined exposure and unverified product identity prevent attribution to either substance. This is a personal report, not a confirmed drug reaction or an estimate of risk.
Read the adverse-experience reportNo clear change: reported experiences
No elbow improvement during combined exposure
An author described no improvement in longstanding elbow symptoms after 14 weeks using a product labeled BPC-157/TB-500 alongside rehabilitation exercises.
Reported use in this account
- Product
- Pen labeled BPC-157/TB-500; full-length thymosin beta-4 identity not established
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Fourteen weeks
Other exposures described: BPC-157; Rehabilitation exercises
The exposure units are inconsistent and the product’s contents were not verified. This combined, fragment-labeled product cannot establish the effects of full-length thymosin beta-4.
Read the original accountApproval status
No thymosin beta-4 or TB-500 product is FDA approved for consumer recovery or performance uses. FDA has specifically described evidence gaps and potential risks for the thymosin beta-4 fragment used in compounding.
Ophthalmic Phase 3 studies completed
RGN-259, a thymosin beta-4 ophthalmic product candidate, has completed Phase 3 dry-eye studies. No thymosin beta-4 or TB-500 product is FDA approved.
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Whether effects in models translate into improved human recovery
- How full-length thymosin beta-4 differs clinically from marketed fragments
- Long-term safety and effects on abnormal blood-vessel or cell growth
- Whether research products and products marketed online have the same identity and manufacturing quality
Summary
Clinical evidence does not establish broad recovery claims. Full-length thymosin beta-4, fragments and marketed products are not interchangeable.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- fdaFDA: bulk substances that may present significant safety risks
FDA summaries of safety concerns and evidence gaps for selected bulk substances used in compounding.
- clinical trialsClinicalTrials.gov: RGN-259 ARISE-2 dry eye study
Registry record for an ophthalmic thymosin beta-4-related study.
- clinical trialsClinicalTrials.gov: RGN-259 ARISE-3 dry eye study
Registry record for an additional ophthalmic thymosin beta-4-related study.
- pubmedThymosin beta-4 and corneal inflammation review
Peer-reviewed review discussing thymosin beta-4 in corneal wound healing and inflammation.